These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19389129)

  • 21. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Brimonidine absorption and release from 1. Day acuvue disposable contact lenses].
    García Delpech S; García Gómez S; Barreiro Rego A; Carrasco Luna J
    Arch Soc Esp Oftalmol; 2001 Oct; 76(10):599-603. PubMed ID: 11685677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
    Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
    Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
    Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of timolol release from silicone hydrogel model contact lens materials using hyaluronic acid.
    Guidi G; Korogiannaki M; Sheardown H
    Eye Contact Lens; 2014 Sep; 40(5):269-76. PubMed ID: 25162288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitosan nanoparticles laden contact lenses for enzyme-triggered controlled delivery of timolol maleate: A promising strategy for managing glaucoma.
    Maulvi FA; Patel AR; Shetty KH; Desai DT; Shah DO; Willcox MDP
    Drug Deliv Transl Res; 2024 Nov; 14(11):3212-3224. PubMed ID: 38407770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
    Chevrier RL; Assalian A; Duperré J; Lesk MR
    Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended wear therapeutic contact lens fabricated from timolol imprinted carboxymethyl chitosan-g-hydroxy ethyl methacrylate-g-poly acrylamide as a onetime medication for glaucoma.
    Anirudhan TS; Nair AS; Parvathy J
    Eur J Pharm Biopharm; 2016 Dec; 109():61-71. PubMed ID: 27664023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
    Feldman RM; Stewart RH; Stewart WC; Jia G; Smugar SS; Galet VA
    Curr Med Res Opin; 2008 Aug; 24(8):2403-12. PubMed ID: 18627642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure.
    Liu JH; Medeiros FA; Slight JR; Weinreb RN
    Ophthalmology; 2010 Nov; 117(11):2075-9. PubMed ID: 20663566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma.
    Quaranta L; Katsanos A; Floriani I; Riva I; Russo A; Konstas AG
    J Clin Pharmacol; 2012 Oct; 52(10):1552-7. PubMed ID: 22110164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma.
    Konstas AG; Maltezos A; Bufidis T; Hudgins AG; Stewart WC
    Eye (Lond); 2000 Feb; 14 ( Pt 1)():73-7. PubMed ID: 10755105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
    Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
    J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits.
    Shafaa MW; Sabra NM; Fouad RA
    Biopharm Drug Dispos; 2011 Dec; 32(9):507-17. PubMed ID: 22028305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple drug delivery from the drug-implants-laden silicone contact lens: Addressing the issue of burst drug release.
    Desai AR; Maulvi FA; Desai DM; Shukla MR; Ranch KM; Vyas BA; Shah SA; Sandeman S; Shah DO
    Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110885. PubMed ID: 32409042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.